Dupilumab Effective in Treating Severe Asthma with Small Airway Dysfunction Jacinthlyn Sylvia29 Oct 2023 9:45 PM ISTA real-life study uncovered the positive effects of the drug Dupilumab on severe asthma patients, marking a significant advancement in asthma...
Require additional efficacy data for Dupixent approval for chronic spontaneous urticaria: USFDA to Sanofi Ruchika Sharma23 Oct 2023 4:44 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Treatment of atopic dermatitis with dupilumab associated with reversible and benign Lymphoid reaction Dr. Shravani Dali20 Oct 2023 10:15 AM ISTTreatment of atopic dermatitis with dupilumab associated with reversible and benign Lymphoid reaction suggests a new study published in the JAMA...
Dupilumab Improves Sleep Quality among Chronic Rhinosinusitis patients with nasal polyps Jacinthlyn Sylvia17 Oct 2023 8:00 PM ISTChronic rhinosinusitis with nasal polyps (CRSwNP) has long been a source of discomfort for many, impacting patients' quality of life and sleep. Now, a...
Sanofi Dupixent sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for USFDA priority review Ruchika Sharma28 Sept 2023 2:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
Dupilumab significantly improves sleep quality and other signs and symptoms in atopic dermatitis patients Dr. Shravani Dali28 Aug 2023 10:00 AM ISTDupilumab significantly improves sleep quality and other signs and symptoms in atopic dermatitis patients suggests a new study published in the...
Dupilumab improves clinical outcomes in patients having chronic rhinosinusitis with nasal polyps Dr. Kamal Kant Kohli26 July 2023 9:30 AM ISTUSA: A recent study published in Allergy & Asthma Proceedings on the efficacy of the human monoclonal antibody Dupilumab in patients with chronic...
Sanofi Dupixent gets nod in India for treatment of adults with moderate-to-severe atopic dermatitis Ruchika Sharma11 July 2023 1:12 PM ISTDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.
Dupilumab lessens disease severity in COPD patients with type 2 inflammation Dr. Kamal Kant Kohli28 Jun 2023 8:00 PM ISTChronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the...
Dupilumab use in atopic dermatitis patients not associated with cancer development Aditi21 April 2023 8:00 PM ISTNewyork: A 5-year retrospective study published in The Journal of Allergy and Clinical Immunology: In Practice concluded that atopic dermatitis...
Dupilumab highly effective in reducing symptoms of eczema in children less than 6 years Dr. Kamal Kant Kohli11 April 2023 9:45 AM IST Dupilumab is a monoclonal antibody that targets a key immune pathway in allergies. According to a new study Researchers at Northwestern Medicine have...
Sanofi Dupixent gets European Commission nod for children aged 6 months to 5 years old with severe atopic dermatitis Ruchika Sharma22 March 2023 12:45 PM ISTDupixent is an injection administered under the skin at different injection sites.
